相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exaggeration of PFS by blinded, independent, central review (BICR)
A. Stone et al.
ANNALS OF ONCOLOGY (2019)
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
Michelle K. Wilson et al.
LANCET ONCOLOGY (2015)
Model free audit methodology for bias evaluation of tumour progression in oncology
Andrew Stone et al.
PHARMACEUTICAL STATISTICS (2015)
Endpoints in cancer clinical trials
F. Fiteni et al.
JOURNAL OF VISCERAL SURGERY (2014)
Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
Jenny J. Zhang et al.
CLINICAL CANCER RESEARCH (2013)
An Audit Strategy for Progression-Free Survival
Lori E. Dodd et al.
BIOMETRICS (2011)
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group
A. M. Stone et al.
EUROPEAN JOURNAL OF CANCER (2011)
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
O. Amit et al.
EUROPEAN JOURNAL OF CANCER (2011)
Measurement error in the timing of events: effect on survival analyses in randomized clinical trials
Edward L. Korn et al.
CLINICAL TRIALS (2010)
Blinded Independent Central Review of the Progression-Free Survival Endpoint
Ohad Amit et al.
ONCOLOGIST (2010)
Overall Survival: A Gold Standard in Search of a Surrogate The Value of Progression-Free Survival and Time to Progression as End Points of Drug Efficacy
Sen H. Zhuang et al.
CANCER JOURNAL (2009)
Overall Survival: Still the Gold Standard Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials
James J. Driscoll et al.
CANCER JOURNAL (2009)
Recommendations for the assessment of progression in randomised cancer treatment trials
J. E. Dancey et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense?
Lori E. Dodd et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Endpoints for assessing drug activity in clinical trials
Richard Pazdur
ONCOLOGIST (2008)
Progression-free survival as an end-point in clinical trials of biotherapeutic agents
Lothar Bergmann et al.
EJC SUPPLEMENTS (2007)
Proposal for the use of progression-free survival in unblinded randomized trials
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Optimizing randomized phase II trials assessing tumor progression
Andrew Stone et al.
CONTEMPORARY CLINICAL TRIALS (2007)
分享论文
